

Country General Information (WHO, 2013)

Total population:	28,829,000	Age group <15/>14 years, %:	29% / 71%
Gender (% F/M):	42.5% / 57.5%	Life expectancy at birth in years (F/M):	78 / 74
GDP (PPP int \$):	53 780	Number of 2nd sub-national administrative level divisions, name:	13, Province
Income status:	High		





Epidemiology

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	11	155	2035	0
Number of relapse cases:	1	No data	No data	0
Total number of cases:	12	155	2035	0
Imported cases (n, %):	2 17%	No data	No data	No data
Gender distribution (% F):	17%	24%	25%	N/A
Age group distribution (% <5/5-14/>14):	(58 / 17 / 17)	(12 / 25 / 63)	(9 / 17 / 74)	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.01	0.44	0.74	N/A
Number of endemic 2nd sub-national administrative level divisions (n):	5	3	17	N/A
Population at risk ¹ (% n/total):	32% (9186737 / 28829000)	12% (3496001 / 28829000)	95% (27358826 / 28829000)	N/A
Was there any outbreak?	No	No	No	N/A
Number of new ² foci:	1	0	0	N/A

N/A = not applicable VL = visceral leishmaniasis ACL = anthroponotic cutaneous leishmaniasis ZCL = zoonotic cutaneous leishmaniasis MCL = mucocutaneous leishmaniasis

Monthly distribution of new (primary) cases January-December

	2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	1	1	2	1	0	1	3	1	0	0	0	0	1
ACL	17	18	14	24	5	11	4	4	7	9	13	29	
ZCL	362	344	225	115	92	56	75	197	123	107	136	203	

Number of new CL cases reported by month in 2013 and 2014

Number of new (primary) VL cases reported by month in 2013 and 2014

Incidence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014
Number of cases and incidence rate³ of CL

Number of cases and incidence rate³ of VL


¹ Defined as "Number of people living in 1st sub-national administrative level endemic areas"


* No data available

² For this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever


³ Incidence rate at the national level

Distribution of new CL (left) and new (primary) VL (right) cases


Incidence of ACL in Saudi Arabia in 2014 at region level per 10 000 population



Incidence of VL Saudi Arabia in 2014 at region level per 10 000 population



Incidence of ZCL in Saudi Arabia in 2014 at region level per 10 000 population



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/HTM/NTD/IDM

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	1983	Year latest national guidelines were published:	2000
Type of surveillance:	Integrated	Is leishmaniasis a notifiable disease (mandatory reporting)?	Yes
Is there a vector control programme?	Yes	Is there a reservoir host control programme?	No
Type of insecticide used for IRS:	Deltamethrin	Number of leishmaniasis health facilities:	249

Diagnosis

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	No data	No data	No data
Number of people screened passively for:	No data	No data	No data	No data
VL cases diagnosed by RDT* (%, # RDT+/total VL cases):	100% (11 / 12)	N/A	N/A	N/A
Proportion of positive RDT* (%, # RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides +/total cases):	0% (0 / 12)	No data	No data	N/A
Proportion of positive slides (%, # slides +/total slides):	N/A (0 / 0)	No data	No data	N/A
Cases diagnosed clinically (%, # clinical cases/total cases):	0% (0 / 12)	No data	No data	N/A
Percentage of cases with HIV-VL coinfection:	0% (0 / 12)	N/A	N/A	N/A

* These indicators apply only for new (primary) VL cases

VL = visceral leishmaniasis

ACL = anthroponotic cutaneous leishmaniasis

ZCL = zoonotic cutaneous leishmaniasis

N/A = not applicable

RDT = rapid diagnostic test

HIV = human immunodeficiency virus

MCL = mucocutaneous leishmaniasis

Treatment and medicines

Is treatment provided free of charge in the public sector?	Yes
Antileishmanial medicines included in the national List of Essential Medicines:	Sodium stibogluconate (SSG), liposomal amphotericin B

TREATMENT OUTCOME

	VL
Proportion of relapse cases: ⁴	8% (1 / 12)
Initial cure rate:	92% (11 / 12)
Failure ⁵ rate:	0% (0 / 12)
Case-fatality rate:	0% (0 / 12)

⁴ A relapse case in this country is defined as: Reappearance of lesion(s) after cure

⁵ A failure case in this country is defined as: Deterioration or no improvement during the treatment period